A. Iurlo, D. Cattaneo, C. Fava, F. Castagnetti, M. Bonifacio, M. D'adda, M. Miggiano, I. Capodanno, C. Elena, L. Levato, A. Scortechini, F. Lunghi, M. Caramella, N. Orofino, M. Maffioli, V. Bellani, Valentina Bonuomo, Selene Grano, Giulia Cotilli, E. Scalzulli, Matteo Dalmazzo, S. Crescenzi, L. Luciano, B. Martino, T. Intermesoli, D. Rapezzi, G. Binotto, M. Tiribelli, Dario Consonni, Fabrizio Pane, Giuseppe Saglio, C. Gambacorti-Passerini, M. Breccia, G. Rosti
2026.1.21CANCER
Abstract
Approximately half of patients with chronic myeloid leukemia (CML) who attempted tyrosine kinase inhibitor (TKI) discontinuation for the first time experienced molecular relapse and restarted TKIs. Although several studies have already investigated first treatment‐free remission (TFR) attempts (TFR1), few previously published articles have focused on the plausibility and predictors of second TFR (TFR2).
Citation format
IURLO, A., et al. Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life italian multicenter study. CANCER, 2026, 132(3): e70261.